EA202090326A1 - Стабилизирующие тример мутации белка оболочки hiv - Google Patents

Стабилизирующие тример мутации белка оболочки hiv

Info

Publication number
EA202090326A1
EA202090326A1 EA202090326A EA202090326A EA202090326A1 EA 202090326 A1 EA202090326 A1 EA 202090326A1 EA 202090326 A EA202090326 A EA 202090326A EA 202090326 A EA202090326 A EA 202090326A EA 202090326 A1 EA202090326 A1 EA 202090326A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
envelope proteins
trimer
mutation protein
protein shell
Prior art date
Application number
EA202090326A
Other languages
English (en)
Other versions
EA038287B1 (ru
Inventor
Йоханнес Петрус Мария Лангедейк
Люси Рюттен
Ника Минди Строкаппе
Дафне Трюан
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Priority claimed from PCT/EP2018/068900 external-priority patent/WO2019016062A1/en
Publication of EA202090326A1 publication Critical patent/EA202090326A1/ru
Publication of EA038287B1 publication Critical patent/EA038287B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Представлены белки оболочки вируса иммунодефицита человека (HIV), имеющие заданные мутации, которые стабилизируют тримерную форму белка оболочки. Белки оболочки HIV, описанные в данном документе, характеризуются увеличенной процентной долей образования тримеров и/или увеличенным выходом тримеров. Также предусмотрены частицы, отображающие белки оболочки HIV, молекулы нуклеиновой кислоты и векторы, кодирующие белки оболочки HIV, а также композиции, содержащие белки оболочки HIV, частицы, нуклеиновую кислоту или векторы.
EA202090326A 2018-06-18 2018-07-12 Стабилизирующие тример мутации белка оболочки hiv EA038287B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178358 2018-06-18
PCT/EP2018/068900 WO2019016062A1 (en) 2017-07-19 2018-07-12 HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM

Publications (2)

Publication Number Publication Date
EA202090326A1 true EA202090326A1 (ru) 2020-04-28
EA038287B1 EA038287B1 (ru) 2021-08-04

Family

ID=62814797

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090326A EA038287B1 (ru) 2018-06-18 2018-07-12 Стабилизирующие тример мутации белка оболочки hiv

Country Status (1)

Country Link
EA (1) EA038287B1 (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189067B1 (en) * 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
MD3512543T2 (ro) * 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Mutații de stabilizare a trimerului proteinei de înveliș HIV

Also Published As

Publication number Publication date
EA038287B1 (ru) 2021-08-04

Similar Documents

Publication Publication Date Title
EA201990715A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
CY1124689T1 (el) Trans-αντιγραφοymeno rna
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
AU2018298422A1 (en) Novel nucleic acid molecules
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202091710A1 (ru) Антитела против cd73 и способы их применения
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
WO2018106615A3 (en) Compositions and methods for enhancing gene expression
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
EA201991093A1 (ru) Способ повышения уровней секреции интерлейкина-2 и полученных из него белков
MY190926A (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EA202092362A1 (ru) Вирусные векторы для нацеливания на ткани глаза
EA202091712A1 (ru) МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA202092069A1 (ru) Композиции и способы лечения макулярной дистрофии
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv